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Summary We performed a multicentre, randomised, double-blind (within-device),
placebo- and active-controlled, parallel-group study to compare the efficacy and
safety of ipratropium bromide plus fenoterol hydrobromide (IB/FEN; Beroduals)
delivered via the novel, propellant-free Respimats Soft MistTM Inhaler (SMI) and
from a chlorofluorocarbon (CFC)-metered-dose inhaler (MDI) in moderate-to-severe
chronic obstructive pulmonary disease (COPD) patients.
After 2-weeks’ run-in (CFC-MDI [IB 20 mg /FEN 50 mg per actuation] two actuations
q.i.d. [MDI 40/100]), 892 patients were randomised to Respimats SMI containing IB
10 mg/FEN 25 mg (Respimats SMI 10/25), IB 20 mg/FEN 50 mg (Respimats SMI 20/50) or
placebo (one actuation q.i.d.), or a CFC-MDI containing IB 20 mg/FEN 50 mg (MDI 40/
100) or placebo (two actuations q.i.d.) for 12 weeks.
Analysis of the primary endpoint (change in forced expiratory volume in 1 s [FEV1]
in the first 60min after dosing [area under the curve; AUC01 h]) on day 85 showed
that the efficacy of Respimats SMI 20/50 (but not Respimats SMI 10/25) was not
inferior to that of MDI 40/100. The safety profile of Respimats SMI was comparable
to CFC-MDI. Switching from MDI 40/100 to Respimats SMI was well tolerated.
Respimats SMI enables a 50% reduction of the nominal inhaled dose of IB/FEN in
COPD patients while offering similar therapeutic efficacy and safety to the CFC-MDI.
& 2004 Published by Elsevier Ltd.
Introduction
Globally, chronic obstructive pulmonary disease
(COPD) is estimated to have been the cause of
2.66 million deaths in all WHO regions in 19991
COPD is also the ‘‘fastest growing cause of death in
the world’s advanced economies’’.2
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Although COPD is characterised by airflow ob-
struction which is largely non-reversible, broncho-
dilators are widely recommended to prevent or
reduce symptoms in patients with the disease, and
inhalation is the preferred route of administration
of these agents.3–6 In stable COPD, the combination
of a short-acting b-agonist and the anticholinergic
ipratropium bromide (IB) achieves greater and
more sustained improvements in forced expiratory
volume in 1 s (FEV1) than either agent alone.
5
Furthermore, the combination of the b2-agonist
fenoterol hydrobromide (FEN) with IB has been
shown to provide effective bronchodilation in
COPD.7 The fixed combination of IB and FEN
(Beroduals; Boehringer Ingelheim GmbH) has been
available as a metered-dose inhaler (MDI) for the
treatment of COPD in a number of countries for
many years.
Although MDIs are the most commonly used
devices for inhaled drug administration in respira-
tory diseases, many patients use them incor-
rectly.8,9 In one study of COPD patients, 40%
performed some essential inhaler manoeuvres
incorrectly;10 if inhaler technique is poor, signifi-
cant amounts of medication may fail to reach the
lungs and hence disease control will be suboptimal.
This may result in the prescribing of higher doses
and additional drugs, thereby increasing drug costs.
Thus, there are medical and economic needs for
improved inhaler devices.
Respimats Soft MistTM inhaler (SMI) is a novel,
propellant-free multidose inhaler with a unique
delivery mechanism that uses the energy released
from a tensioned spring to force a pre-defined
metered volume of drug solution through an
innovative nozzle array (the uniblock); these
components are illustrated in Fig. 1. This mechan-
ism produces a very fine aerosol for inhalation (the
soft mist). Respimats SMI is easy to use, with the
patient simply having to twist the base of the
device 1801, press the dose-release button, and
inhale the soft mist. The medication is provided as
a solution in a cartridge that is inserted into the
device before first use. Each cartridge contains 120
actuations. Respimats SMI generates a slow-mov-
ing cloud with a fine particle fraction of 66%;11–13
this value is approximately 2.5 times that for
MDIs.12 These characteristics together with a
relatively long duration of dose release (approxi-
mately 1.2 s)13 significantly reduce oropharyngeal
and increase lung deposition compared with chlor-
ofluorocarbon- (CFC) and hydrofluoroalkane-(HFA)
MDIs14–16 and may also reduce the need for hand–
lung co-ordination.
The aim of this study was to show whether the
more efficient delivery of a bronchodilator via
Respimats SMI seen in deposition studies is borne
out in a large-scale clinical trial, so allowing a
smaller dosage to be given via Respimats SMI to
achieve the same efficacy seen with CFC-MDI. This
was done by comparing the efficacy and safety in
COPD patients of IB/FEN delivered from Respimats
SMI (at a dosage of 10 mg IB/25 mg FEN per actuation
or 20/50 mg per actuation; one actuation q.i.d.) and
a CFC-MDI at a dosage of 40/100 mg (taken as two
actuations of 20/50 mg each) q.i.d. The 40/100 mg
q.i.d. MDI dosage was chosen because it has been
established as the standard therapeutic dosage for
maintenance therapy of COPD in practice. Smaller
dosages were chosen for the two Respimats SMI
groups (one-quarter and one-half of the usual
therapeutic dosage) on the strength of the results
from dose-ranging and dose–response studies of
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Figure 1 Sectional diagram of Respimats SMITM, show-
ing the main components of the device.
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IB/FEN in asthma patients17,18 and in corresponding
studies of IB alone in COPD patients.19,20
Patients and methods
Patients
Patients aged X40 years were eligible for inclusion
if they had a diagnosis of COPD, as indicated by
FEV1p65% of predicted normal21 and FEV1/FVC
(forced vital capacity) p70% at screening, and a
smoking history of 410 pack-years. Exclusion
criteria included: a history of clinically significant
diseases other than COPD; recent upper or lower
respiratory tract infection (RTI); history of asthma,
allergic rhinitis or atopy, or blood eosinophil count
4600/mm3. The use of b-adrenergic and anti-
cholinergic bronchodilators (short or long-acting) as
concomitant medication was not allowed during
the study, except as rescue medication (salbutamol
only). Other drugs that were not allowed during the
study were b-blockers, oral corticosteroids at a
dosage of 410mg prednisolone/day or its equiva-
lent (except for the treatment of COPD exacerba-
tions), antihistamines, anti-leukotrienes, sodium
cromoglycate, nedocromil sodium, and chronic
oxygen therapy.
Theophylline was permitted, as were stable
doses of inhaled and low-dose oral corticosteroids.
Appropriate washout periods for bronchodilators
were used before pulmonary function tests.
Study design
This multicentre, randomised, double-blind (with-
in-device), parallel group, placebo- and active-
controlled study was conducted in 92 centres in the
UK, Germany and Austria between February 1998
and April 1999. The study was conducted in
accordance with the Declaration of Helsinki and
Good Clinical Practice Guidelines. The local Ethics
Committee or Institutional Review Board for each
centre approved the protocol and all patients gave
written informed consent.
During the 2-week run-in period, all patients
received Beroduals CFC-MDI (IB 20 mg/FEN 50 mg
per actuation) two actuations q.i.d. Patients who
experienced a COPD exacerbation during this
period were not eligible for inclusion into the
study. The remaining patients were randomised to
one of five treatments for 12 weeks:
* Respimats SMI IB 10 mg/FEN 25 mg, one actuation
q.i.d.,
* Respimats SMI IB 20 mg/FEN 50 mg, one actuation
q.i.d.,
* CFC-MDI IB 20 mg/FEN 50 mg per actuation, two
actuations q.i.d. (MDI 40/100),
* Respimats SMI placebo, one actuation q.i.d., or,
* CFC-MDI placebo, two actuations q.i.d.
Patients were randomised in blocks of eight in a
2:2:2:1:1 ratio. Treatment was open-label for
devices and double-blind for the IB/FEN dose, i.e.
active and placebo CFC-MDIs were of identical
appearance and active and placebo Respimats SMI
devices were of identical appearance. A double-
dummy technique was not used because inhalation
of excipients from both devices would have made it
impossible to assess any switch effect or the
incidence of adverse events (AEs) caused by the
excipients of either device. Patients were trained
in the use of both inhaler devices at the screening
visit before the run-in period. Salbutamol CFC-MDI
100 mg per actuation prn was used as rescue
medication.
Assessments
Schedule of assessments
The study consisted of five clinic visits: a screening
visit (Visit 1) followed by a 2-week run-in, and then
Visits 2–5 on days 1, 29, 57 and 85. At Visit 1,
demographic data were recorded and patients
provided a medical history (previous 5 years) and
underwent a physical examination (including blood
pressure and pulse rate), pulmonary function tests
(baseline FEV1 and FVC and testing for reversibility
to 200 mg salbutamol via CFC-MDI), electrocardio-
gram (ECG), clinical laboratory parameters, and
training in the use of study inhalers. At Visits 2–5,
FEV1, FVC, pulse rate and blood pressure were
recorded pre-dose and 5, 15, 30, 60min post-dose.
At Visit 2, pulmonary function testing started
between 7.00 and 10.00 a.m., and at subsequent
visits, testing started within 30min of the actual
start time at Visit 2, to minimise the influence of
diurnal pulmonary variation. All AEs that occurred
during the study were recorded. Laboratory tests,
physical examination and ECG were repeated on
day 85. Patients completed a daily diary card on
which they recorded morning and evening peak
expiratory flow rate (PEFR), study and rescue
medication use and COPD symptom scores.
Efficacy parameters
The primary efficacy endpoint was the change from
pre-dose in FEV1 in the first 60min after dosing,
calculated as the area under the FEV1-time curve
between 0 and 1 h (AUC0–1 h) on day 85.
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The secondary efficacy endpoints were: change
in FEV1 (AUC0–1 h) on days 1, 29 and 57; total FEV1
calculated as the AUC between 0 and 1 h (TAUC0–1 h)
on day 85; the peak FEV1 achieved in the first
60min after dosing on days 1 and 85 (measured as
the change from the pre-dose value); FVC on all
test-days (days 1, 29, 57 and 85), and the weekly
mean values of (a) pre-dose morning and evening
PEFR, (b) total daily inhaled rescue medication,
and (c) day and night-time symptom scores.
Symptoms were scored on a scale from 0 (no
symptoms) to 4. For night-time symptom score, 4
represented wakingX4 times per night, and for the
daytime score, it represented symptoms that
prevented the patient attending work and engaging
in all normal activities.
Safety
Safety variables recorded included: AEs; blood
pressure and pulse rate on test-days; 12-lead
ECG, clinical laboratory parameters (haematology,
biochemistry and urinalysis), and physical exam-
ination at screening and at the end of the study.
The effect of switching from CFC-MDI to Respimats
SMI was assessed by comparing morning and
evening PEFR, respiratory symptoms, rescue med-
ication use and respiratory AEs in the first 2 weeks
of randomised treatment with the corresponding
values during the last week of the run-in (or, in the
case of respiratory AEs, during both weeks of the
run-in).
Statistical analysis
Statistical analyses were specified in the trial
protocol before the study began. The primary
efficacy objective was to demonstrate that at least
one of the two doses of IB/FEN via Respimats SMI
gave a bronchodilatory response that was non-
inferior to (i.e. equivalent to or better than) that
obtained from IB/FEN via CFC-MDI. To do this, the
null hypothesis was that each dose of IB/FEN via
Respimats SMI was therapeutically inferior to that
delivered by CFC-MDI (as measured by the change
in FEV1 in the first 60min after dosing (AUC0–1 h) on
day 85) by a margin of at least 0.05 L. The
alternative hypothesis, i.e. that IB/FEN Respi-
mats SMI was not inferior to IB/FEN CFC-MDI (using
the same 0.05 L margin) would be proven if the
lower 95% confidence limit (CL) for the mean
difference (Respimats SMI minus CFC-MDI) lay
above 0.05 L at the 2.5% level (used rather than
5%, as each dose via Respimats SMI was compared
separately to the CFC-MDI).
A sample of 182 patients per active treatment
group would give a power of approximately 80% to
conclude that either IB/FEN dose delivered via
Respimats SMI was not inferior to IB/FEN delivered
via the MDI at the 2.5% level of significance,
allowing for two primary endpoint comparisons,
given that the formulations were equal. Placebo
groups were to include half as many patients as
active treatment groups, giving a total of 728
patients.
The primary endpoint was evaluated by analysis
of covariance (ANCOVA), including the factors
country and treatment with baseline at Visit 2
(day 1) as covariate.
Data from patients who received at least one
dose of randomised treatment, and for whom the
pre-dose FEV1 preceding the first dose of rando-
mised treatment and at least one post-dose FEV1
was available, constituted the clinic spirometry
intention-to-treat (ITT) population; the clinic
spirometry per-protocol (PP) population excluded
those patients with major protocol violations or
protocol deviations that potentially obscured
treatment response. Primary and secondary effi-
cacy analyses of all spirometry data were per-
formed on the clinic spirometry PP population,
and confirmatory analyses done on the clinic
spirometry ITT population. Patients without
major protocol violations and who had at least 4
days morning (or evening) PEFR data for both
run-in and randomised treatment periods consti-
tuted the diary morning (or evening) PEFR PP
population. All randomised and treated patients
(the safety population) were included in AE
summaries.
Results
Patients
Of 1117 patients enrolled, 225 were not entered
(mainly because of failure to fulfil inclusion/
exclusion criteria). The remaining 892 patients
were randomised to treatment (safety population;
Table 1). As two randomised patients had missing
pre-dose pulmonary function test data on day 1,
the clinic spirometry ITT population consisted of
890 patients. A total of 54 patients from this
population had serious protocol violations, which
were mainly those affecting Visit 2 (concomitant
medication violations, exacerbations of COPD, or
upper or lower RTIs) and elevated eosinophil
counts. The remaining patients ðn ¼ 836Þ consti-
tuted the clinic spirometry PP population. The
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diary morning PEFR PP population contained 790
patients and its evening counterpart 786. In total,
158 (17.7%) patients discontinued the trial prema-
turely, due to: AEs ðn ¼ 112Þ; administrative rea-
sons ðn ¼ 37Þ; non-compliance with protocol
ðn ¼ 12Þ; loss to follow-up ðn ¼ 9Þ; withdrawal of
consent ðn ¼ 16Þ or other reasons ðn ¼ 9Þ: The
proportion of withdrawals was comparable across
treatment groups.
Baseline and demographic characteristics were
generally comparable across treatment groups
(Tables 2 and 3). The median duration of COPD
was 8 years and all patients were either current or
ex-smokers. Pulmonary function measurements
were also comparable across groups with the
exception of a slight imbalance in reversibility to
salbutamol at screening: increase in FEV1 30min
after salbutamol 200 mg was greater in the MDI 40/
100 group than in other groups. Overall, the mean
FEV1 was 1.16 L, with a mean % of predicted normal
FEV1 of 41% and mean FEV1/FVC ratio of 56%. The
range of severity of airflow limitation, using the
GOLD classification5 is shown in Table 3. Pulmonary
therapies taken during the 6 weeks before the run-
in were also comparable across treatment groups,
except that slightly fewer Respimats SMI 10/25 and
Respimats SMI 20/50 patients were on inhaled
corticosteroids while slightly more Respimats
SMI 20/50 patients were receiving oral corticoster-
oids (14% vs. overall mean of 11%). During
randomised treatment the use of inhaled corticos-
teroids and oral xanthines remained fairly
stable; however, the use of oral corticosteroids
increased due to the treatment of COPD exacerba-
tions, which were an exclusion criterion during the
run-in period and before study enrolment. Baseline
characteristics for the clinic spirometry PP popula-
tion were similar to the clinic spirometry ITT
population.
Efficacy
Primary endpoint
Analysis of the primary endpoint (change from pre-
dose in FEV1 [AUC0–1 h] in the first 60min after
dosing on day 85) in the clinic spirometry PP
population showed that the difference between
the mean values for Respimats SMI 20/50 and MDI
40/100 was only 0.001 L (lower 2.5% CL0.0323 L).
As the lower CL for this difference was greater than
0.05 L, Respimats SMI 20/50 was shown to be
non-inferior to MDI 40/100 ðP ¼ 0:0013Þ: Non-
inferiority was not demonstrated for Respimats
SMI 10/25 vs. MDI 40/100, as the treatment
difference was 0.020 L with a lower 2.5% CL of
0.053 L. These results are shown graphically in
Fig. 2. The supportive analysis of the primary
endpoint on the clinic spirometry ITT population
produced comparable results.
Time–response curves for change in FEV1 in the
first 60min after dosing on day 85 showed that the
responses to IB/FEN in the three active treatment
groups were similar, and superior to the responses
in the two placebo groups (Fig. 3).
Secondary endpoints
The results for the change in FEV1 in the first 60min
after dosing on day 1 (AUC0–1 h) mirrored those of
the analysis of the primary endpoint on day 85;
non-inferiority to MDI 40/100 was demonstrated for
Respimats SMI 20/50, but not for Respimats SMI
10/25. For days 29 and 57, however, non-inferiority
to MDI could not be shown for either Respimats SMI
dose.
Results for the remaining secondary endpoints,
namely FEV1 (TAUC0–1 h) on day 85, peak FEV1
achieved in the first 60min after dosing on days 1
and 85 (measured as the change from the pre-dose
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Table 1 Patient disposition.
Population Respimats Respimats MDI 40/100 Respimats MDI placebo Total
SMI 10/25 SMI 20/50 SMI placebo
Enrolled 1117
Entered and treated 217 224 220 114 117 892
(safety population)
Clinic spirometry 216 224 220 114 116 890
ITT
Clinic spirometry 202 208 209 106 111 836
PP
Prematurely discontinued (%) 36 (16.6) 41 (18.3) 39 (17.7) 23 (20.2) 19 (16.2) 158 (17.7)
SMI: Soft MistTM Inhaler; MDI: metered-dose inhaler; ITT: intention-to-treat; PP: per-protocol.
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Table 2 Demographic and baseline characteristics of all randomised patients (safety population; mean values unless otherwise indicated).
Characteristic Respimats SMI Respimats SMI MDI 40/100 Respimats SMI MDI placebo Total
10/25 20/50 (n¼ 220) placebo (n¼ 117) (n¼ 892)
(n¼ 217) (n¼ 224) (n¼ 114)
Sex M/F (N) 151/66 163/61 161/59 85/29 76/41 636/256
Agen, years (range) 63.1 (38–87) 62.7 (29–83) 62.8 (37–83) 64.9 (28–84) 64.4 (40–88) 63.3 (28–88)
Smoking history (%)
Ex-smoker 54 55 57 59 56 56
Smoker 47 46 43 41 44 44
Pack years (range) 39.3 (10–200) 36.0 (10–96) 37.4 (10–114) 36.0 (8–102) 36.4 (10–99) 37.2 (8–200)
Median duration of COPD, years (range)w 9.0 (0–48) 9.0 (0–50) 7.0 (0–36) 9.5 (1–50) 8.0 (1–50) 8.0 (0–50)
FEV1, (L) (SD) 1.16 (0.42) 1.17 (0.44) 1.15 (0.46) 1.14 (0.39) 1.14 (0.43) 1.16 (0.43)
% Predicted FEV1 (SD) 42 (13) 41 (13) 40 (13) 41 (13) 42 (13) 41 (13)
FEV1 increase at 30min (%) (SD) 15 (16) 16 (21) 20 (20) 14 (15) 16 (18) 17 (19)
Number (n and %) of patients with FEV1 90 (41) 93 (42) 111 (51) 44 (39) 53 (46) 391 (44)
reversibility of X15%y
FEV1/FVC (%) (SD) 55 (11) 56 (11) 55 (11) 56 (12) 56 (11) 56 (11)
Pulmonary therapies taken during the
6 weeks before run-in (% patients)
Inhaled glucocorticoids 63 64 72 75 69 68
Oral glucocorticoids 9 14 10 12 11 11
Short-acting inhaled b-agonists 50 52 53 52 54 52
Long-acting inhaled b-agonists 13 16 18 21 21 17
Anticholinergics 17 12 14 11 13 14
b-agonist/anticholinergic combination 37 33 37 35 27 35
Oral xanthines 38 39 33 38 33 36
SMI: Soft MistTM Inhaler; MDI: metered-dose inhaler; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SD: standard
deviation.
nInclusion of patients below the age of 40 years was a protocol violation.
w0 represents o6 months’ duration.
yPost-bronchodilator FEV1 missing for five patients.
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value) and FVC on all test-days, confirmed the
analysis of the primary endpoint. All FEV1 and FVC
analyses showed a trend to higher bronchodilator
response for Respimats SMI 20/50 compared with
Respimats SMI 10/25, with consistently higher
point estimates for the higher Respimats SMI dose.
There were small improvements in morning and
evening PEFR during the study for most treatment
groups except for evening PEFR in the two placebo
groups (Figs. 4 and 5). There was little difference
between groups for either daytime or night-time
symptom scores or rescue medication use.
Safety and tolerability
The safety profile of Respimats SMI 10/25 and
Respimats SMI 20/50 was comparable to that of
MDI 40/100. The most commonly reported AEs were
associated with the respiratory system (Table 4).
COPD exacerbation was the most common event in
all groups and was slightly more frequent in the
Respimats SMI 20/50 group (27%) than in other
groups (18–21%). Dyspnoea was less frequent in the
Respimats SMI groups (7.8% and 7.6%) than in the
other groups (9.4–12.3%). Coughing was reported
less frequently in the Respimats SMI 20/50 group
than in the Respimats SMI 10/25 and MDI 40/100
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Figure 2 Difference between treatments in bronchodi-
lator response to ipratropium bromide/fenoterol (change
in forced expiratory volume in 1 s (FEV1) from pre-dose
value expressed as area under the curve (AUC01 h))
during the first 60min after dosing on day 85 in adults
with chronic obstructive pulmonary disease (COPD).
Differences shown (mean and 95% confidence intervals)
are those between each Respimats Soft MistTM Inhaler
(SMI) group and the metered-dose inhaler (MDI) group,
and between the two Respimats SMI groups, and are
adjusted for country and treatment baseline (pre-dose on
day 1). Data shown are from clinic spirometry per-
protocol population (n ¼ 619; active treatments only).
Table 3 Categorisation of all randomised patients (safety population, n ¼ 892) according to extent of airflow
limitation (baseline FEV1 as % predicted) using the GOLD classification (5).
Number of patients in each stage (%)
Respimats SMI Respimats SMI MDI Respimats SMI MDI
10/25 20/50 40/100 placebo placebo
(n¼ 217) (n¼ 224) (n¼ 220) (n¼ 114) (n¼ 117)
Mild (Stage I) 2 (0.9) 2 (0.9) 1 (0.5) 2 (1.8) 0 (0)
Moderate (Stage IIa) 86 (39.6) 86 (38.4) 88 (40.0) 41 (36.0) 52 (44.4)
Moderate (Stage IIb) 102 (47.0) 104 (46.4) 96 (43.6) 53 (46.5) 52 (44.4)
Severe (Stage III) 27 (12.4) 31 (13.8) 33 (15.0) 17 (14.9) 12 (10.3)
Unclassified 0 (0) 1 (0.5) 2 (0.9) 1 (0.9) 1 (0.9)
FEV1: forced expiratory volume in 1 s; MDI: metered-dose inhaler; SMI: Soft Mist
TM Inhaler.
Figure 3 Change in forced expiratory volume in 1 s
(FEV1) from pre-dose value in first 60min after dosing on
day 85, adjusted for country and treatment baseline
(pre-dose on day 1). Data shown are from clinic
spirometry per-protocol population ðn ¼ 836Þ: SMI, Soft
MistTM Inhaler; MDI, metered-dose inhaler.
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groups. There were fairly similar incidences of
upper RTI and urinary tract infections across the
treatment groups. Incidences of all other AEs were
low across all groups (o3%).
A total of 112 (13%) patients discontinued
randomised treatment because of AEs; worsening
of COPD was reported by 82 patients, worsening of
other pre-existing disease by 6, and other AEs by
24. The number of patients who discontinued
treatment because of AEs was similar across
treatment groups (range 10.0–15.8%).
A total of 63 (7.1%) patients reported serious
adverse events (SAEs) during randomised treat-
ment. The most frequent SAE was COPD exacerba-
tion ðn ¼ 24Þ; which occurred more often in active
treatment groups (Respimats SMI 10/25, 2.3%;
Respimats SMI 20/50, 4.9%; MDI 40/100, 2.7%)
than placebo groups (0.9% in both). Three patients
in the Respimats SMI 20/50 group and one in the
MDI 40/100 group developed pneumonia. All other
SAEs occurred in no more than one or two patients
per treatment group. Five patients who developed
SAEs died, but none of these events were con-
sidered to be related to the trial drug.
There were no clinically relevant differences
across treatment groups regarding effects on vital
signs or changes in laboratory parameters, ECG and
physical examinations. There were no spontaneous
reports of paradoxical or administration-related
bronchoconstriction during the study.
The comparison of the first 2 weeks of rando-
mised treatment with the last week of the run-in
period showed the absence of any switch effect for
either active Respimats SMI treatment as mea-
sured by morning and evening PEFR and symptom
scores. However, an increase in rescue medication
use was observed during the first 2 weeks of
randomised treatment compared with the last
week of the run-in, across all treatment groups.
On average, patients in the Respimats SMI 10/25
and Respimats SMI 20/50 groups used slightly less
rescue medication than the other groups. There
was a significant increase in the incidence of all
respiratory AEs (mainly COPD exacerbations, bron-
chitis and dyspnoea) during the first 2 weeks of
randomised treatment compared with the 2 run-in
weeks in all treatment groups, except Respimats
SMI 10/25.
Discussion
The aim of the present study was to compare the
efficacy and safety of IB/FEN (Beroduals) delivered
from Respimats SMI and a CFC-MDI in COPD
patients. The efficacy of both Respimats SMI 10/
25 and Respimats SMI 20/50 were superior to
placebo, and Respimats SMI 20/50 was non-inferior
to MDI 40/100. Thus, since the safety and toler-
ability of Respimats SMI 20/50 and Respimats SMI
10/25 were shown to be very similar to that of MDI
40/100, delivery via Respimats SMI enables a 50%
reduction in the nominal dose of IB/FEN in this
patient population compared with the MDI. This is
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Figure 4 Mean weekly morning pre-dose peak expiratory
flow rates (PEFR) adjusted for country and treatment
baseline (run-in week). Run-in week is the last week
before the first dose of randomised treatment; data
shown are from diary morning PEFR per-protocol popula-
tion ðn ¼ 790Þ: MDI¼metered-dose inhaler; SMI¼ Soft
MistTM Inhaler.
Figure 5 Mean weekly evening pre-dose peak expiratory
flow rates (PEFR) adjusted for country and treatment
baseline (run-in week). Run-in week is the last week
before the first dose of randomised treatment; data
shown are from diary evening PEFR per-protocol popula-
tion ðn ¼ 786Þ: SMI¼ Soft MistTM Inhaler; MDI ¼ metered-
dose inhaler.
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consistent with the results of deposition studies
which have shown that the proportion of drug
deposited in the lung after inhalation from Respi-
mats SMI is much greater than that delivered from
a MDI.14–16
The analysis of the primary endpoint on day 85
showed that the efficacy of Respimats SMI 20/50
(but not Respimats SMI 10/25) was not inferior to
that of MDI 40/100. Except for the change in FEV1
(AUC0–1 h) on days 29 and 57, analyses of secondary
endpoints supported the non-inferiority of the
Respimats SMI 20/50 dose compared with the MDI
40/100 group. The pre-specified analyses of the
primary endpoint used a very strict definition of
non-inferiority, i.e. the lower 95% CL for the
difference between treatments had to be above
0.05 L. However, had a slightly less strict infer-
iority margin been used, i.e. 0.06 L, then Respi-
mats SMI 20/50 would have been shown to be non-
inferior to MDI 40/100 on all four test-days, as the
mean differences between treatments were all
above 0.05 L. Furthermore, a trend towards a
higher bronchodilator response for Respimats SMI
20/50 compared with Respimats SMI 10/25 was
observed with consistently higher point estimates
for the higher Respimats SMI dose. These observa-
tions appear to make the Respimats SMI 20/50
dose a rational choice.
The choice of dosage for the MDI treatment arm
was made because 40/100 mg q.i.d. via CFC-MDI has
been established as the optimal dosage of IB/FEN
for maintenance therapy in COPD patients in
clinical practice. This decision was taken after
consultation with regulatory agencies to whom the
data has since been submitted to support applica-
tions for a product licence for IB/FEN in Respimats
SMI. We have already mentioned that the aim of
this study was to prove the principle that a patient
can obtain the same bronchodilator efficacy as
from the currently used MDI dosage by delivering a
half or a quarter of this dosage via Respimats SMI.
It is possible that the findings of our study could
have been strengthened if a second CFC-MDI arm
(20/50 mg q.i.d.) had been included, in case the 40/
100 mg q.i.d. dosage was on the plateau of the
dose–response curve. However, the results of all
the FEV1 and FVC analyses in the current study
showed a trend in favour of a higher bronchodilator
response for IB/FEN 20/50 mg via Respimats SMI
than for IB/FEN 10/25 mg. Furthermore, the results
of the study by Kunkel and colleagues in asthma
patients18 showed that when a cumulative dose of
IB/FEN 320/800 mg was given via Respimats SMI and
MDI, the bronchodilator response was significantly
greater via Respimats SMI, and a dose of only half
this size from Respimats SMI (160/400 mg) gave
equivalent bronchodilation to 320/800 mg via MDI.
The results of the present study confirm the
results of initial dose-ranging studies that demon-
strate that, when delivered by Respimats SMI, IB in
COPD patients,19 FEN in asthma patients22 and an
IB/FEN combination in asthma patients17 are just as
efficacious as when delivered via CFC-MDI but at a
smaller dose. Another cumulative dose–response
study has also shown that Respimats SMI improves
the delivery of IB compared with MDIs in patients
with COPD,20 providing a significantly greater
bronchodilator effect, at half the dose given via
MDI, from 45min after the first dose of the series to
45min after the final dose. The efficacy results of
the present study are also consistent with results
of 12-week studies of Respimats SMI containing
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Table 4 Number of patients reporting adverse events (AEs) (%) during randomised treatment with ipratropium
bromide plus fenoterol via Respimats SMITM or CFC-MDI or matching placebos in the safety population ðn ¼ 892Þ:
The ‘‘most common AEs’’ are defined as those reported by 43% of patients in at least one group and events are
described by WHO preferred term.
Number of patients (and %
of total) reporting at least
one adverse event
Respimats
SMI 10/25
(n¼ 217)
Respimats
SMI 20/50
(n¼ 224)
MDI 40/100
(n¼ 220)
Respimats
SMI placebo
(n¼ 114)
MDI placebo
(n¼ 117)
Total with any adverse event 122 (56) 125 (56) 115 (52) 57 (50) 57 (49)
Most common AEs:
COPD exacerbation 44 (20.3) 60 (26.8) 46 (20.9) 22 (19.3) 21 (17.9)
Dyspnoea 17 (7.8) 17 (7.6) 24 (10.9) 14 (12.3) 11 (9.4)
URTI 15 (6.9) 13 (5.8) 9 (4.1) 7 (6.1) 3 (2.6)
Coughing 12 (5.5) 7 (3.1) 13 (5.9) 4 (3.5) 3 (2.6)
UTI 7 (3.2) 5 (2.2) 2 (0.9) 3 (2.6) 3 (2.6)
CFC: chlorofluorocarbon; MDI: metered-dose inhaler; FEV1: forced expiratory volume in 1 s; URTI: upper respiratory tract
infection; UTI: urinary tract infection.
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IB/FEN or IB alone in adults with COPD or asthma. In
a study of IB/FEN in adult asthma patients, the
change in FEV1 (AUC0–6 h) from test-day baseline on
day 85 demonstrated that both Respimats SMI
doses (20 mg IB/50 mg FEN and 10 mg IB/25 mg FEN)
were non-inferior to the CFC-MDI 40 mg IB/100 mg
FEN.23 In a study of IB alone in COPD patients which
used the same outcome measure, IB doses of 20 and
40 mg q.i.d. delivered by Respimats SMI were also
shown to be therapeutically non-inferior to IB 40 mg
q.i.d. delivered via a conventional CFC-MDI.24
Overall, the safety profiles of both Respimats
SMI 20/50 and Respimats SMI 10/25 are compar-
able to that of MDI 40/100. This confirms previous
observations of comparable safety profiles for
Respimats SMI and CFC-MDIs for the delivery of IB
in COPD patients.20,24 In the current study, the
incidences of AEs and withdrawals were similar
between treatment groups. The higher incidence of
COPD exacerbations in the Respimats SMI 20/50
group is a surprising result which has not been
found in any of the other studies in the Respimats
SMI clinical development programme. It was prob-
ably a chance occurrence, although one contribut-
ing factor may have been that a greater proportion
of patients in this treatment group received oral
corticosteroids before the study, implying that
more of the patients in this group were prone to
exacerbations.
Concern has been expressed over any possible
adverse effects of changing the propellant or
formulation in inhaler devices, the so-called
‘switch effect’. A number of parameters were
measured to assess any switch effects. A compar-
ison of the first 2 weeks’ randomised treatment vs.
the two-week run-in period showed no switch
effect for either of the active Respimats SMI
treatments as assessed by morning or evening PEFR
or symptom scores. There was, however, an
increase in respiratory AEs (COPD exacerbations,
dyspnoea and bronchitis) compared with the run-in
period across all treatment groups, except Respi-
mats SMI 10/25. There was also an increase in
rescue medication use in all groups, although this
was less pronounced in the Respimats SMI 20/50
and Respimats SMI 10/25 groups. The increase in
respiratory AEs and the associated increase in
rescue medication use may be explained by the
fact that patients who developed COPD exacerba-
tions were withdrawn from the study if these
occurred during the run-in period, but not if they
occurred after randomisation.
The inclusion and exclusion criteria used in this
study were chosen to ensure as far as possible that
the patients enrolled were a representative group
of COPD patients. Patients had to be at least 40
years old, have a diagnosis of COPD (FEV1p65%
predicted and FEV1/FVCp70% at screening), and
have a smoking history of410 pack-years. Patients
were excluded if they had a history of asthma,
allergic rhinitis or atopy, a raised eosinophil count,
or were on antihistamines, leukotriene modifiers or
cromones. Reversibility of airflow obstruction was
measured at baseline to better characterise the
study population, but it was not used as an
inclusion or exclusion criterion, and patients were
not stratified at randomisation according the
degree of reversibility. A little less than half of
the patients had FEV1 reversibility of 15% or more,
suggesting an asthmatic component to their dis-
ease. If we had tested our hypothesis separately on
the two subgroups of patients either side of the 15%
reversibility threshold, we might have been able to
show whether our results were affected by the
presence of this asthmatic component. This was not
done however, as the size of the subgroups would
have given insufficient statistical power to detect a
treatment difference at the chosen level of
significance.
In conclusion, Respimats SMI enables a 50%
reduction of the nominal daily dose of IB/FEN in
COPD patients while offering similar therapeutic
efficacy and safety to the corresponding CFC-MDI.
Furthermore, each individual dose was delivered
from Respimats SMI in just one actuation, rather
than the two actuations needed with the CFC-MDI.
Respimats SMI thus has the potential to be a useful
alternative to MDIs for the delivery of inhaled drugs
to this patient population.
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